Search Results for "Sunitinib"
Original Source: [Articles] Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on standard treatments. As far as we are aware, this is t...
Matching Channels
None
Matching News
Sunitinib shows promise against metastatic renal cell carcinoma
Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some...
Review provides reassurance over stopping sunitinib
Sunitinib does not cause kidney cancer metastasis to speed up after treatment ends, despite mouse studies that suggest otherwise, claim researchers (Cell Reports, online 7 February 2013). They rev...
No Post-Therapy Harm Seen with Sunitinib (CME/CE)
(MedPage Today) -- Metastatic growth of renal cell carcinoma did not increase after completion of treatment with sunitinib (Sutent), alleviating concerns that had arisen in recent animal studies, an a...
ASCO: Sunitinib Helps with Brain Metastases
CHICAGO (MedPage Today) -- Treatment with stereotactic surgery plus sunitinib might be an alternative to surgery plus whole-brain radiation for controlling metastases from lung or breast cancer, resea...
COX-2 inhibitor extends sunitinib activity in renal cell carcinoma
The effectiveness of sunitinib for the treatment of renal cell carcinoma could be enhanced with the addition of a cyclooxygenase-2 inhibitor, study findings show.
[News] No rebound tumour growth after sunitinib treatment
Patients with metastatic kidney cancer treated with the tyrosine kinase inhibitor sunitinib have no rebound tumour growth after stopping treatment, according to a new analysis.
Sunitinib does not cause lingering risks for cancer patients after their treatment ends
Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the larges...
Sunitinib adds no survival to erlotinib for lung cancer
NEW YORK (Reuters Health) - In a phase III trial in patients with refractory non-small-cell lung cancer (NSCLC), adding sunitinib to erlotinib improved the response rate and progression-free survi...
Matching PubMed Articles
Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour.
WHAT IS KNOWN AND OBJECTIVE: Sunitinib can improve progression-free survival and overall survival in patients with advanced pancreatic neuroendocrine tumor (PNET). From clinical trial, most commonly r...
Life-Threatening Complications Associated with the Tyrosine Kinase Inhibitor Sunitinib Malate.
Adverse events associated with sunitinib, such as cardiac toxicities, renal damage, and hemostatic complications, are well known. The authors report 3 cases in which patients experienced severe life-t...
We evaluated the effects of sunitinib monotherapy and in combination with cisplatin in human gastric cancer cell lines. Sunitinib showed antiproliferative effect in gastric cancer cells line with high...
Blue toe syndrome and sunitinib.
We present a patient with metastatic renal cell carcinoma treated with sunitinib, a multitargeted tyrosine kinase inhibitor. The patient experienced bilateral blue toe syndrome which we related to sun...
Sunitinib is a tyrosine kinase inhibitor for GIST and advanced renal cell carcinoma. Diclofenac is used in cancer pain management. Coadministration may mediate P450 toxicity. We evaluate their interac...
